All News

Pharmacy Times will be covering the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which gathers pharmacy professionals working in malignant and classical hematology in New Orleans, Louisiana.

Based on the ALIFE 2 trial results, the investigators do not advise the routine use of low-molecular-weight heparin in women with recurrent pregnancy loss and confirmed inherited thrombophilia.

A modified secukinumab dosing regimen produced outcomes on par with currently recommended intervals in patients with moderate-to-severe psoriasis, but longer follow-ups are needed to confirm the findings.

Study finds urgent need for aggressive expansion of pre-exposure prophylaxis among people who inject drugs to reduce the spread of HIV.

Dawn L. Hershman, MD, MS, Columbia University Medical Center, New York, NY, presents her findings at the 2022 San Antonio Breast Cancer Symposium.

RSVpreF produced vaccine efficacy of 66.7% against respiratory syncytial virus-associated lower respiratory tract illness in older adults.

Researchers discovered the most common single gene mutation that causes treatment-resistance in first- line ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.

Cognitive behavioral therapy and pharmacotherapy have been found equally effective treating anxiety disorders, yet some patients are less likely to begin medication treatment.

Dr. Jaclyn Boyle is assistant dean for Student Success and associate professor of Pharmacy Practice at Northeast Ohio Medical University.

An effective shingles vaccine has been available in China since 2020, but vaccine hesitancy persists in at-risk populations.

Clinical trial results found that second-line treatment with trastuzumab deruxtecan led to significantly longer overall survival compared with trastuzumab emtansine.

Both vaccine hesitancy and antivax beliefs are largely fueled by inaccurate reports of adverse effects from vaccines, a new study finds.

DESTINY-Breast02 clinical trial results show trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in progression-free and overall survival.

Study finds textured breast implants do not increase the risk of anaplastic large-cell lymphoma, which has grown in incidence since 2008.

Study finds men are more likely to be prescribed statins and women are more likely to be advised to make lifestyle changes to lessen the risk of cardiovascular disease.

Implants could produce and deliver monoclonal anti-HIV antibody therapy for at least 1 year.

Tumor microenvironment differences in Black women may explain disparities in outcomes for those with residual tumors after chemotherapy treatment for ER–positive/HER2-negative breast cancer.

Breast cancer expert joined a panel to discuss aromatase inhibitors at the San Antonio Breast Cancer Symposium (SABCS) on December 6, 2022.

Larger corporations might consider holding some sort of financial literacy training for pharmacy employees.

Commonly published metformin study designs in patients with type 2 diabetes may not be sufficiently addressing residual confounding.

Future research should investigate which therapies with new mechanisms of action add incremental benefit to existing treatment regimens for non-small cell lung cancer.

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

The current flu hospitalization rate is the highest observed this early in a flu season in over a decade.

Phase 3 monarchE trial assesses distant relapse free-survival, invasive disease-free survival, and overall survival for the treatment of HR-positive/HER2-negative-, node-positive, high-risk early breast cancer.

RxPonder clinical trial results indicate that racial disparities continue to be a major health care challenge.

Zuranolone is a rapid-acting, once-daily, 14-day oral short course therapy for adult patients with major depressive disorder and postpartum depression.

Omega-3 fatty acids among the micronutrients found to provide a benefit to cardiovascular health.

PHP shows promise extending survival in patients with inoperable intrahepatic cholangiocarinomas or extrahepatic cholangiocarinoma with liver metastases.